Market research
TBD.F Emerald Health Therapeutics, Inc
F EUR Not available
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.63
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.63
About
About Emerald Health Therapeutics, Inc
Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production, distribution, and sale of recreational and medical cannabis in Canada. It offers dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products under the SYNC Wellness, fuse, Emerald, and Souvenir brands. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada. As of November 10, 2022, Emerald Health Therapeutics, Inc. operates as a subsidiary of Skye Bioscience, Inc.
Research context
Emerald Health Therapeutics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TBD.F discussion.
5 years, 7 months ago
Emerald Health Therapeutics, Inc is currently in a long term downtrend where the price is trading 19.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
Emerald Health Therapeutics, Inc's total revenue sank by 63.7% to $3M since the same quarter in the previous year.
Its net income has increased by 33.4% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 96.2% to $-541K since the same quarter in the previous year.
Based on the above factors, Emerald Health Therapeutics, Inc gets an overall score of 3/5.